Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Comment by narmacon Mar 15, 2022 10:04am
204 Views
Post# 34514724

RE:RE:RE:RE:RE:RE:RE:RE:RE:No news , no leaks?

RE:RE:RE:RE:RE:RE:RE:RE:RE:No news , no leaks?,,my best guess is there is complacency and infighting among the insiders and management. Hepa wants the operation to fail in order to pick us up at a stink pricing,,,,they are probably using a 3rd party short,,,exchange regulators are not interested,,,our team is in a pickle as to how to push forward,,,,,no other pharma seems willing to be in business with the insiders and weak management unless major change is made,,,the team are refusing to give up their golden goose. No trials in China or the Asian block is telling!,,,all interested parties we were told about have backed out of the deal offerings,,,the added failures over the years have caught up to pinocchio,,,we are between a rock and a hard place,,,,,no matter what the C19 trial data tells us there will be very limited excitement from the market. The managemnt team has continued to fail month after month since BoM results. The market respects accomplishments. The C19 trial which was supposed to be run last year with first data out by end of April/May is still in disarray. Again,,,,this company is seen as a personal banking system for management. Presentations still mirror what was said 5 years ago. The business world outside is way ahead of anything our team can dream up. 
<< Previous
Bullboard Posts
Next >>